Communiqués Syntara Limited

Actions

SNT

AU0000312480

Recherche biotechnologique et médicale

Cours en clôture Australian S.E. 05/10/2026			Varia. 5j.	Varia. 1 janv.
0,0220 ^AUD	+4,76%		-4,35%	-37,14%

21/09	Syntara reçoit un remboursement de 4,7 millions d'AU$ au titre du crédit d'impôt recherche pour l'exercice 2026 ; l'action grimpe de 9%	MT
27/08	Syntara Limited publie ses résultats pour l'exercice clos le 30 juin 2026	CI

Communiqués

08/11/23	University of Birmingham : Promising target for liver disease treatments identified; Inhibiting a protein involved in liver inflammation has the potential to reduce or stop fibrosis in patients with non-alcoholic steatohepatitis, trial finds	AQ
03/10/23	Pharmaxis to focus on clinical-stage drug development	AQ
13/07/23	Pharmaxis says majority of patients in fibrosis trial see significant improvement	AQ
25/05/23	Pharmaxis extends scarring collaboration after encouraging results	AQ
12/04/23	Pharmaxis to accelerate plans for myelofibrosis combination study after FDA talks	AQ
15/06/22	Pharmaxis : Application for quotation of securities - PXS	PU
30/05/22	Pharmaxis : Application for quotation of securities - PXS	PU
30/05/22	Pharmaxis : Application for quotation of securities - PXS	PU
31/03/22	Pharmaxis : R&D Showcase Presentations Webinar 2	PU
29/03/22	Pharmaxis : R&D Showcase Presentations Webinar 1	PU
31/01/22	Pharmaxis : Updated Investor Presentation	PU
31/01/22	Pharmaxis : Presentation - quarterly investor update	PU
10/01/22	Pharmaxis : Response to ASX Aware Query	PU
22/12/21	Pharmaxis : Application for quotation of securities - PXS	PU
30/11/21	Pharmaxis : Application for quotation of securities - PXS	PU
24/11/21	Pharmaxis : Security Purchase Plan	PU
24/11/21	Pharmaxis : Application for quotation of securities - PXS	PU
09/11/21	Generic Tiotropium bromide 18 µg DPI, developed by Phargentis, receives approval in 28 European countries	AQ
02/11/20	Pharmaxis : FDA Bronchitol Approval to Generate Cash Flows for Pharmaxis	BU
20/08/20	Pharmaxis Ltd : - FDA Gives Pharmaxis Green Light to Start Myelofibrosis Phase 2 Study	AQ
19/08/20	FDA Gives Pharmaxis Green Light to Start Myelofibrosis Phase 2 Study	PU
16/12/19	Pharmaxis : Trading Halt	PU
24/11/19	Pharmaxis : Investor Presentation	PU
08/09/17	Pharmaxis Ltd Boehringer Ingelheim is Initiating Phase IIa Study for the Development of a New Treatment for Diabetic Retinopathy - a Leading Cause of Vision-Loss	AW
08/09/17	Boehringer Ingelheim Initiates Phase IIa Study of Compound Acquired from Pharmaxis Ltd in Debilitating Liver Disease NASH	AW